Skip to content
Screener

EPS (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
$7.94+26.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$12.23-4.5%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$0.90+23.1%
uniQure logo
uniQureQURE
-$1.22-76.8%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$0.03-100%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$1.15-5.5%

Other financials

Income statement

See full
Revenue$3.6M
Gross profit$3.5M
Operating income-$130.5M+3.3%
Net income-$127.6M-2.8%

Balance sheet

See full
Cash & equivalents$204.6M+41.8%
Total debt$37.7M-21.4%
Total equity$835.2M-18.7%
Total assets$1.2B-0.7%

Cash flow

See full
Operating cash flow-$97.0M-28.8%
CapEx$805.0K-81.2%
Free cash flow-$97.8M-22.9%

Valuation

See full
Market cap$3.92B+88.3%
Enterprise value$3.76B+89.0%
P/S1,089×+1,084×

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-54.9%+34.3pp
Debt / equity0.0×
Current ratio8.4×-1.9×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:08 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001714899-26-000097
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Loss from operations(130,541)(134,963)(267,898)(280,543)
Interest and other income, net2,98810,84411,89823,454
Net loss$(127,553)$(124,119)$(256,000)$(257,089)
Other comprehensive loss:
Net unrealized loss on marketable securities, net of tax(1,287)(1,098)(2,651)(1,081)
Comprehensive loss$(128,840)$(125,217)$(258,651)$(258,170)
Net loss per share, basic and diluted$(0.68)$(0.72)$(1.37)$(1.50)
Weighted average number of shares outstanding, basic and diluted187,314,501171,449,847186,977,612171,336,568

Item 1. Financial Statements (Unaudited)

FAQ

What is Denali Therapeutics Inc.'s EPS (diluted)?
Denali Therapeutics Inc. (DNLI) reported EPS (diluted) of -$0.68 in Q2 2026.
How has Denali Therapeutics Inc.'s EPS (diluted) changed year-over-year?
Denali Therapeutics Inc.'s EPS (diluted) increased by 5.6% year-over-year, from -$0.72 to -$0.68.
What is the long-term trend for Denali Therapeutics Inc.'s EPS (diluted)?
Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s EPS (diluted) has grown at a 5.6% compound annual growth rate (CAGR), from -$2.39 to -$2.97.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Denali Therapeutics Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude